Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors

Product is added to your Wishlist
Global Biologics Market

Global Biologics Market -Analysis and Forecast (2017-2025) (Focus on Pipeline Analysis, Product Type, Therapeutic Application, Country Analysis, and Market Dynamics)

The global biologics market generated a revenue of $238.8 million in 2016. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future.

SKU: BH028A
Published Year: 2017
 
 

The biologics or a biopharmaceutical product means a pharmaceutical semi synthesized from different biological sources. In contrast to completely synthesized drugs, biologics are generally made up of living cells, gene components, sugars, proteins, nucleic acids, tissues,  allergenic, and also vaccines. The useful components listed above are isolated from living sources and combined, to cure the disease with minimal side effects. Biologics products often represent the pioneer developments in biotechnology research and often aid medical practitioners in treating a variety of illnesses    and conditions which presently have no other treatments available. Other factor such as the ability of biologics to facilitate complete cure of a disease with minimal side effects is   boosting the growth of the market.

Geographically, biologics have registered near double digit annual growth rate, whereas, the pharmaceutical drugs registered only single digit annual growth rate, in the past five years. This double digit growth was largely fuelled by the substantial investments of the major pharmaceutical companies, who realized the potential of the market quite early. 

The research study comprises of extensive analysis of various factors effecting the global biologics market. The entire market has been estimated and validated through three different approaches namely, by product, by therapeutic areas and by geographical destination. In terms of product, the market has been categorized into monoclonal antibody (mAbs), hormones, growth factors, fusion proteins, cytokines, therapeutic enzymes, vaccines, blood factors, and anticoagulants. The mAbs are the dominating other types in terms of sales and therapeutic enzymes is the highest growing type.

In terms of therapeutic areas the market is segmented into oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases. The market is dominated by oncology related products and infectious diseases related products are expected to grow at the highest rate. In terms of geography, the market was segmented into North America, Europe, Latin America, Middle East, Africa and Rest of the World. In terms of sales, North America currently dominates the other geographical regions whereas, Middle East and Africa together are expected to grow at the highest rate. 

The key players which have significant contributions to the biologics market are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Gilead Sciences, Inc., AbbVie Inc., Amgen Inc., Lilly,Bristol-Myers Squibb, Novo Nordisk, Merck KGaA, Allergan, Plc, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, and Biocon Ltd.

The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the global biologics market.

The answers to the following key questions can be derived from this report:
•    What are the major market drivers, challenges and opportunities in the global biologics market and their case studies?
•    How did the biologics market evolve and what is its scope in the future?
•    What is the market share of the leading segments and sub-segments of the global biologics market in 2016 and 2025?
•    How will each segment of the global biologics market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2025?
•    What are the influencing factors that may affect the market share of the key players?
•    How will the industry evolve during the forecast period between 2016 and 2025?
•    What are the key developmental strategies implemented by the key players to stand out in this market?
•    Which geographical location will contribute to the highest sales of biologics?

This research report aims at answering various aspects of the global biologics market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global biologics market and assesses the factors governing the same.

TABLE OF CONTENT
Executive Summary
1 Report Scope and Methodology
1.1. Scope of the Report
1.2. Global Biologics Market Segmentation 
1.3. Key Learnings 
1.4. Research Methodology
1.4.1.  Key Data Points From Secondary Sources 
1.4.2.  Key Data Points From Primary Sources 
1.4.3.  Top-Down Approach (Segmental Analysis)
1.4.4.  Bottom-Up Approach (Segmental Analysis)
1.4.5.  Assumption and Limitations 
1.4.6.  Data and Prediction Modelling 
2.  Market Overview
2.1. Introduction
2.2. Market Dynamics
2.2.1.  Market Drivers
2.2.2.  Market Restraints
2.2.3.  Market Opportunities
3.  Global Biologics Market by Therapeutics
3.1. Overview
3.2. Market Trend Analysis
3.3. Oncology
3.4. Cardiovascular
3.5. Immunological Diseases
3.6. Infectious Diseases
3.7.  Metabolic Diseases
4.  Global Biologics Market by Product
4.1. Overview
4.2. Market Trend Analysis
4.3. Monoclonal Antibodies (mAbs)
4.4. Hormones
4.5. Growth Factors
4.6. Fusion Proteins
4.7. Cytokines
4.8. Therapeutic Enzymes
4.9. Blood Factors and Anticoagulants
4.10.  Vaccines
5.  Global Biologics Market by Geography
5.1. Overview
5.2. North America
5.2.1.  The U.S.
5.2.2.  Canada
5.3. Europe
5.3.1.  Germany
5.3.2.  France
5.3.3.  The U.K.
5.3.4.  Italy
5.3.5.  Spain
5.4. Asia Pacific (APAC)
5.4.1.  Japan
5.4.2.  China
5.4.3.  Australia
5.4.4.  India
5.5. Latin America
5.6. Middle East Africa
5.7. Rest of the World (RoW)
6.  Competitive Landscape
6.1. Key Developments and Strategies
6.2. Regulatory Body Clearance
6.3. New Product Launches and Developments
6.4. Merger & Acquisitions
6.5. Agreements, Joint Ventures and Partnerships
6.6. Business Expansion
6.7. Others
6.8. Patent Landscape
7.  Company Profiles
7.1. AbbVie Inc.
7.2. Allergan Plc 
7.3. Amgen Inc.
7.4. Astellas Pharma Inc.
7.5. AstraZeneca PLC
7.6. Bayer AG
7.7. Biocon Ltd.
7.8. Boehringer Ingelheim GmbH
7.9. Bristol-Myers Squibb Company
7.10.  Eli Lilly and Company
7.11. F. Hoffmann-La Roche AG 
7.12.  Gilead Sciences, Inc.
7.13.  GlaxoSmithKline Plc
7.14.  Johnson & Johnson
7.15.  Merck & CO., Inc.
7.16.  Merck KGaA
7.17.  Novartis AG
7.18.  Novo Nordisk
7.19.  Pfizer Inc.
7.20.  Sanofi
7.21.  Teva Pharmaceuticals Industries Limited
List of Tables
1 Regulatory Types of Biological Products
2 Pharmaceutical Spending Trends
3 Global Pharmaceutical Product Rank by Sales (Conventional and Biologics)
4 Biosimilar Products Approved by the EMA as of May, 22, 2017
5 Biosimilar Products Approval Pathway in the U.S. (as of May, 22, 2017)
6 351(k) Applications Under First-Cycle Review
7 Top Selling mAbs, 2016
8 Biosimilars in Development by Chinese Companies
9 Global Biologics Drug Discovery Market by Therapeutic Area, 2014-2025
10 Biologics & Indications (Oncology)
11 Biologics & Indications (Cardiovascular Disease)
12 Biologics & Indications (Immunological Disorder)
13 Biologics & Indications (Infectious disease)
14 Biologics & Indications (Metabolics)
15 Biologics & Indications (Hematology)
16 Global Biopharmaceuticals Market Size, by Region 2014-2025, ($Billion)
17 Regulatory Body Clearance
18 New Product Launches and Developments
19 Merger & Acquisitions
20 Agreements, Joint Ventures and Partnerships
21 Business Expansion
22 Awards, Certifications and Other Developments
23 Patents Granted to Companies
24 Overview: AbbVie Inc.
25 Overview: Allergan Plc
26 Overview: Amgen Inc.
27 Overview: Astellas Pharma Inc. 
28 Overview: AstraZeneca PLC
29 Overview : Bayer AG
30 Overview : Biocon Ltd.
31 Overview : Boehringer Ingelheim GmbH
32 Overview : BRISTOL-MYERS SQUIBB COMPANY
33 Overview : Eli Lilly and Company
34 Overview : Hoffmann-La Roche AG 
35 Overview : GILEAD SCIENCES, INC.
36 Overview : GlaxoSmithKline Plc
37 Overview : JOHNSON & JOHNSON
38 Overview : Merck & CO., Inc.
39 Overview : Merck KGaA
40 Overview : Novartis AG
41 Overview : NOVO NORDISK
42 Overview : Pfizer Inc.
43 Overview : Sanofi
44 Overview : Teva Pharmaceuticals Industries Limited.
List of Tables
1 Approval Pathways for Small-Molecule Drugs
2 Global Pharmaceutical Sales (Conventional Vs Biologics), ($Billion)
3 Global Pharmaceutical Sales (Conventional Vs Biologics) % share ($Billion)
4 Top Pharmaceutical Market 
5 Top Biologics Market 
6 Global Biologic Drug Sales ($Billion)
7 Growth Rate: Patented Biologics Vs Biosimilars
8 Market Revenue: Patented Biologics Vs Biosimilars ($Billion) 
9 Biologic Molecule Scenarios in the U.S. after Biosimilar Introduction
10 Global Biologics Drugs Market by Class, ($Billion)
11 Global Biologic Drugs Market , 2016
12 Global Biologic Drugs Market , 2025
13 Biologic Drugs by Indications, ($Billion)
14 Biologic Drugs by Indications, 2016
15 Biologic Drugs by Indications, 2025
16 Investigational Biologics by Indications
17 Global Biologic Drugs Market: Regional Prospective 
18 Global Biologic Drugs Demand, 2016
19 Global Biologic Drugs Market by Region, $Billion 
20 Global Biologic Drugs Market by Region, 2016
21 Global Biologic Drugs Market by Region, 2025
22 Research Methodology
23 Data Triangulation
24 Key Data Points From Secondary Sources 
25 Key Data Points From Primary Sources 
26 Top-Down  Approach (Segmental Analysis)
27 Bottom-Up Approach (Segmental Analysis)
28 Assumptions and Limitations
29 Clinical Trail Products Type Share by Therapeutic Areas
30 Global  Biologics  Market Size Therapeutic Areas,  2016 and 2025, ($Billion)
31 Global Oncology Biologics Products Market Size,  2014-2025, ($Billion)
32 Global Cardiovascular Biologics Products Market Size,  2014-2025, ($Billion)
33 Global Market Size of  Products for Immunological Diseases,  2014-2025 ($Billion)
34 Global Market Size of  Products for Infectious Diseases,  2014-2025 ($Billion)
35 Global Market Size of  Products for Metabolic Diseases,  2014-2025, ($Billion)
36 Global Market Size of  Products ,  2014-2025, ($Billion)
37 Different Types of Biologics or Biopharmaceuticals
38 Global Biopharmaceutical Market Size,  2014 and 2025, ($Billion)
39 Global mAbs Market Size,  2014 and 2025 ($Billion)
40 Market Size of Top mAbs Products,  2014 and 2025 ($Billion)
41 Global Hormones Market Size,  2014 and 2025 ($Billion)
42 Market Size of Top Hormone Products,  2014 and 2025 ($Billion)
43 Global Growth Factors Market Size,  2014 and 2025, ($Billion)
44 Market Size of Top Growth Factor Products,  2014 and 2025 ($Billion)
45 Global Fusion Proteins Market Size,  2014 and 2025 ($Billion)
46 Market Size of Top Fusion Protein Products,  2014 and 2025, ($Billion)
47 Global Cytokine Market Size,  2014 and 2025, ($Billion)
48 Market Size of Top Cytokine Products,  2014 and 2025 ($Billion)
49 Global Therapeutic Enzymes Market Size,  2014 and 2025, ($Billion)
50 Market Size of Top Therapeutic Enzyme Products,  2014 and 2025, ($Million)
51 Global Blood Factors and Anticoagulants Market Size,  2014 and 2025, ($Billion)
52 Market Size of Top Blood Factors and Anticoagulant Products,  2014 and 2025, ($Billion)
53 Global Vaccines Market Size,  2014 and 2025 ($Billion)
54 Market Size of Top Recombinant Vaccines,  2014 and 2025 ($Billion)
55 Global Scenario 
56 Figure: North America Biologic Market Size, 2014 and 2025 ($Billion)
57 Country Analysis, North America
58 Europe Biologics Market Size,  2014 and 2025, ($Billion)
59 Country Analysis, Europe
60 Asia Pacific Biologic Market Size,  2014 and 2025 ($Billion)
61 Country Analysis, Asia Pacific
62 Latin America Biologic Market Size,  2014 and 2025, ($Billion)
63 Country Analysis, Latin America
64 Share of Key Development and Strategies
65 Total Number of Strategies and Developments
66 AbbVie Inc.:Product Portfolio
67 Financials
68 AbbVie Inc.:  Net Sales by Geographic Destination (2014-2016)
69 AbbVie Inc. : SWOT Analysis
70 Allergan Plc: Product Portfolio
71 Financials
72 Allergan Plc: Net Sales by Business Segments (2015-2016)
73 Allergan Plc: Net Sales by Business Segment (2014)
74 Allergan Plc: SWOT Analysis
75 Amgen Inc.: Product Portfolio
76 Amgen Inc. : Overall Financials (2014-2016)
77 Amgen Inc. :  Net Sales by Geographic Destination (2014-2016)
78 Amgen Inc. : SWOT Analysis
79 Astellas Pharma Inc. : Overall Financials (2014-2016)
80 Astellas Pharma Inc. : Net Sales by Product Type (2014-2016)
81 Astellas Pharma Inc.  : Net Sales by Geographic Destination (2014-2016)
82 Astellas Pharma Inc. : SWOT Analysis
83 AstraZeneca PLC: Product Portfolio
84 AstraZeneca PLC : Overall Financials, 2014-2016
85 AstraZeneca PLC : Net Revenue by Business Segment, 2014-2016
86 AstraZeneca PLC : Revenue across Different Geographies, 2014-2016
87 AstraZeneca PLC: SWOT Analysis
88 Bayer AG: Product Portfolio
89 Bayer AG : Overall Financials, 2014-2016
90 Bayer AG : Net Revenue by Business Segment, 2014-2016
91 Bayer AG: Net Revenue by Geographic Destination, 2014-2016
92 Bayer AG: SWOT Analysis
93 Biocon Ltd.: Product Portfolio
94 Biocon Ltd. : Overall Financials, 2015-2017
95 Biocon Ltd.: Net Revenue by Business Segment, 2015-2017
96 Biocon Ltd. : Net Revenue by Pharma Business Segment, 2014-2016
97 Biocon Ltd. : Revenue across Different Geographies, 2014-2016
98 Biocon Ltd.: SWOT Analysis
99 Boehringer Ingelheim GmbH: Product Portfolio
100 Boehringer Ingelheim GmbH : Overall Financials (2014-2016)
101 Boehringer Ingelheim GmbH : Net Sales by Product Type (2014-2016)
102 Boehringer Ingelheim GmbH : Net Sales by Geographic Destination (2014-2016)
103 Boehringer Ingelheim GmbH: SWOT Analysis
104 BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio
105 BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2016)
106 BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Product Type (2014-2016)
107 BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Geographic Destination (2014-2016)
108 BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
109 Eli Lilly and Company: Product Portfolio
110 Eli Lilly and Company : Overall Financials (2014-2016)
111 Eli Lilly and Company : Net Sales by Product Type (2014-2016)
112 Eli Lilly and Company : Net Sales by Geographic Destination (2014-2016)
113 Eli Lilly and Company: SWOT Analysis
114 F. Hoffmann-La Roche AG : Product Portfolio
115 Roche AG: Overall Financials, (2013–2016)
116 Roche AG: Revenue across Different Geographies, (2013-2016)
117 Roche AG: Net Revenue by Business Segment, (2013-2016)
118 Roche AG: SWOT Analysis
119 GILEAD SCIENCES, INC.: Product Portfolio
120 GILEAD SCIENCES, INC. : Overall Financials (2014-2016)
121 GILEAD SCIENCES, INC. : Net Sales by Geographic Destination (2014-2016)
122 GILEAD SCIENCES, INC. : SWOT Analysis
123 GlaxoSmithKline Plc: Product Portfolio
124 GSK: Overall Financials (2013-2016)
125 GSK: Net Revenue by Business Segments (2013-2016)
126 GSK: Net Revenue by Geography (2013-2015)
127 GSK: Net Revenue by Geography (2016)
128 GlaxoSmithKline Plc: SWOT Analysis
129 JOHNSON & JOHNSON: Product Portfolio
130 JOHNSON & JOHNSON: Overall Financials (2014-2016) 
131 JOHNSON & JOHNSON : Net Revenue by Business Segment (2014-2016)
132 JOHNSON & JOHNSON : Net Revenue by Region (2014-2016)
133 JOHNSON & JOHNSON: SWOT Analysis
134 Merck & CO., Inc.: Product Portfolio
135 Merck & CO., Inc.: Overall Financials (2013-2016)
136 Merck & CO., Inc.: Net Revenue by Business Segments (2013-2014)
137 Merck & CO., Inc.: Net Revenue by Business Segments (2015-2016)
138 Merck & CO., Inc.: Net Revenue by Geography (2013-2014)
139 Merck & CO., Inc.: Net Revenue by Geography (2015-2016)
140 Merck & Co., Inc. : SWOT Analysis
141 Merck & CO., Inc. KGaA: Overall Financials, (2014-2016)
142 Merck & CO., Inc. KGaA: Net Revenue by Business Segments, (2014-2016)
143 Merck & CO., Inc. KGaA: Net Revenue by Geography, (2014)
144 Merck & CO., Inc. KGaA: Net Revenue by Geography, (2015-2016)
145 Merck KGaA : SWOT Analysis
146 Novartis AG: Product Portfolio
147 Novartis: Overall Financials (2013-2016)
148 Novartis: Net Revenue by Business Segments, (2013-2014)
149 Novartis: Net Revenue by Business Segments (2015-2016)
150 Novartis: Net Revenue by Geography  (2013-2016)
151 Novartis AG: SWOT Analysis
152 NOVO NORDISK: Product Portfolio
153 Novo Nordisk: Overall Financials, 2014-2016
154 Novo Nordisk: Net Revenue by Business Segment, 2014-2016
155 Novo Nordisk: Revenue across Different Geographies, 2014-2016
156 NOVO Nordisk: SWOT Analysis
157 Pfizer Inc.: Product Portfolio
158 Pfizer: Overall Financials (2013-2016)
159 Pfizer: Net Revenue by Geography (2013-2016)
160 Pfizer: Net Revenue by Business Segments (2013-2014)
161 Pfizer: Net Revenue by Business Segments (2015-2016)
162 Pfizer Inc. : SWOT Analysis
163 Sanofi: Product Portfolio
164 Sanofi: Overall Financials (2014-2016)
165 Sanofi: Net Sales by Business Segments (2014-2016)
166 Sanofi: Net Sales by Geographic Destination (2014-2016)
167 Sanofi: Net Sales by Franchise (2014-2016)
168 Safoni: SWOT Analysis
169 Teva Pharmaceuticals Industries Limited.: Product Portfolio
170 Teva Pharmaceutical Industries Limited: Overall Financials, (2013-2016)
171 Teva Pharmaceutical Industries Limited : Net Revenue by Business Segments, (2013-2016)
172 Teva Pharmaceutical Industries Limited: Net Revenue by Geography, (2013-2016)
173 Teva Pharmaceutical Industries Ltd.: SWOT Analysis

A biologic drug or biopharmaceutical mean a pharmaceutical product semi synthesized from different biological sources. In contrast to completely synthesized drugs, biologics are generally made up of living cells, gene components, sugars, proteins, nucleic acids, tissues,  allergenics,  and also vaccines.  The useful components listed above are isolated from living sources and combined using recombinant DNA (rDNA) technology, to cure the disease with minimal side effects. Biologics involve complex manufacturing procedures and are required to be maintained at pre-determined conditions as they are highly sensitive to changes in ambience. Consequently, companies need to invest huge amounts in terms of capital, to meet the standards, which will eventually increase the cost of biologics.

The introduction of biologic therapies gave a new ray of hope for people suffering from chronic inflammatory diseases. Biologics effected their life not only by reducing dependency on health and welfare systems but also by improving their physical function to live independently. The entry of biosimilars makes these effective therapies more affordable, though the concern of after effects still exists. Some industry experts also express their caution regarding the entry of biosimilars, which might add to the concerns of safety and after effects of the therapies.

The research report analyses various factors effecting the global biologics market and forecasts the growth of the biologics market. In the report, the entire market has been estimated and validated through three different approaches namely, by product, by therapeutic areas and by geographical destination. In addition, the report also provides insights about present pipeline of the key players having significant contributions to the market, expiry period of patents of top products dominating the market and their impact on the market after patent expiration. 

The global biologics market generated a revenue of $238.8 million in 2016. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future. Moreover, ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories in the development of novel therapeutic biologic drugs.
This gain will largely be driven by robust growth in the emerging markets and increasing adoption of monoclonal antibodies (MABs) and human insulin for the treatment of patients. In addition, governments in some markets (including the U.S. and Europe) have introduced biosimilar pathways as a measure to further the competition in this area.

In 2016, mAbs maintained their ranking as the highest selling class of biologics, with their U.S. sales reaching ~$37.6 billion, an 18.3% growth over their 2015 sales, vaulting Roche, with 11 monoclonal in the market, into the top spot among companies with biologic products. The growth of the mAbs sector was driven by a high growth in the sales of both mAbs for oncology and anti-inflammatory disorders. 

The biologics or biopharmaceutical products find their application across wide range of therapeutic areas namely, oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases, among others. The growing awareness of biologics and its efficiency in treating deadly diseases has nudged small molecule drugs out of the top positions in terms of sales. The biologics find their application especially in the field of oncology. The biologics pipeline include many of its products devoted to oncology and its related diseases. With its high incidence rate of 70% over next two decades, and present burden over the society makes cancer a critical issue needed to be dealt with strict measures to reduce the number of prevalent cases. Biologics help in curing cancer types of disseminated disease or internally located tumors which are difficult to be treated through conventional methods such as radiotherapy and surgery. In 2016, the biologics market was valued at $238 billion, predominantly represented by monoclonal antibodies. The biologics market for cancer is anticipated to reach $155 billion by 2025. Apart from cancer, immunological diseases, cardiovascular and metabolic diseases represent the majority of the shares of the global biologics market. In 2016, immunological diseases was the second largest application segment after oncology, with $66 billion in sales.

Both the North American and European markets are dominating the other markets in terms of biologics sales, followed by Asia Pacific. However, due to the technological advancements in healthcare and toxicology in other markets such as Asia Pacific, it is expected to take over the top position in terms of biologics sales. The current biosimilars market is dominated by Europe which was driven by technically advanced healthcare infrastructure and high patient awareness & regulatory harmonization. Due to high incidence rates of diseases in the emerging markets, many companies are investing huge sums in these markets to address the unmet needs of the patients. All the developed markets except the U.S., are contributors to the total biosimilars sales. Most of the players in biosimilars market remain focused on the developed markets only. 

In past decade, China’s pharmaceutical market has witnessed a double digit growth. This has attracted several major pharmaceutical companies to commercialize their products in China. But the major barriers for foreign companies are regulations binding the Chinese markets and cultural differences as well. Therefore, partnership with the local companies was the only option left to the foreign companies to commercialize their products in the region.

The report provides in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each. Some of the key players are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Gilead Sciences, Inc., AbbVie Inc., Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb GmbH, Novo Nordisk, Merck KGaA and Allergan, Plc.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields

OUR HAPPY CLIENTS


related reports

 

OUR CLIENTS